Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo

Aflatoxin B1 (AFB1), the most potent member of the aflatoxin family of hepatocarcinogens, upon metabolic activation reacts with DNA and forms a population of covalent adducts. The most prevalent adduct, 8,9-dihydro-8-(N7-guanyl-)-9-hydroxyaflatoxin (AFB1-N7-dG), as well as the AFB1 formamidopyrimidi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Carcinogenesis (New York) 2004-06, Vol.25 (6), p.1045-1051
Hauptverfasser: Alekseyev, Yuriy O., Hamm, Michelle L., Essigmann, John M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1051
container_issue 6
container_start_page 1045
container_title Carcinogenesis (New York)
container_volume 25
creator Alekseyev, Yuriy O.
Hamm, Michelle L.
Essigmann, John M.
description Aflatoxin B1 (AFB1), the most potent member of the aflatoxin family of hepatocarcinogens, upon metabolic activation reacts with DNA and forms a population of covalent adducts. The most prevalent adduct, 8,9-dihydro-8-(N7-guanyl-)-9-hydroxyaflatoxin (AFB1-N7-dG), as well as the AFB1 formamidopyrimidine adduct (AFB1-FAPY), resulting from imidazole ring opening of the major adduct, are thought to be responsible for mutations caused by AFB1. The AFB1-N7-dG lesions are rapidly removed in Escherichia coli and mammals, whereas the AFB1-FAPY lesions persist in mammalian cells, which along with the higher stability of this lesion suggests that AFB1-FAPY might significantly contribute to the observed toxicity and carcinogenicity of AFB1 in higher organisms. Other workers have shown in vitro evidence that AFB1-FAPY lesions are substrates for both nucleotide excision repair (NER) and base excision repair (BER). The present study, done in vivo, utilized a modified host cell reactivation assay and showed that AFB1-FAPY lesions are preferentially repaired in E.coli by NER. Comparisons of repair in wild-type, NER-deficient (uvrA), BER-deficient (mutM) and NER/BER double mutant E.coli strains transformed with plasmids enriched for AFB1-N7-dG or AFB1-FAPY lesions indicate that both lesions are efficiently repaired by NER-proficient cells (both wild-type and BER-deficient strains). We have found that the level of activity of the reporter gene is significantly affected by the presence of either lesion in NER-deficient strains due to the lack of repair. This effect is similar in NER-deficient and NER/BER-deficient strains indicating that BER (specifically in the strains we investigated) does not contribute significantly to the repair of these lesions in vivo. Consistent with this finding, in vitro analysis of AFB1-FAPY adduct excision by purified MutM and its functional analog human 8-oxoguanine DNA glycosylase using site-specifically modified oligonucleotides indicates that this lesion is a poor substrate for both proteins compared with canonical substrates for these enzymes, such as 7,8-dihydro-8-oxoguanine and methylformamidopyrimidine.
doi_str_mv 10.1093/carcin/bgh098
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_219301056</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>729198081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3388-745a8dad3b60a7d192efbab0197c61d0551d70d0a662f363588dfc80cd7fbb483</originalsourceid><addsrcrecordid>eNpFkEFv1DAQhS0EokvhyBVZSBxDx3FiO8dSFQqqxKEgob1YE9thXbJxsJNl8-8x2og9zWE-vaf3EfKawXsGDb8yGI0frtqfO2jUE7JhlYCiZAqekg2wihec8-qCvEjpEYAJXjfPyQWrZFVyxjbkcN31OIWjH-gHRrsQ97j3NoxL9Pn6wVG0djZTohgdHaPrXHTD5LHvFxrdiD46S9uFTjtHh9n0LkzeOuqOxicfhpWhI067P7jQ3HPwh_CSPOuwT-7Vei_J94-3327uivuvnz7fXN8XhnOlClnVqCxa3gpAaVlTuq7FFlgjjWAW6ppZCRZQiLLjeZxStjMKjJVd21aKX5K3p9wxht-zS5N-DHMccqUuWcOBQS0yVJwgE0NKeaIe83qMi2ag_0nWJ8n6JDnzb9bQud07e6ZXqxl4twKYDPZdxCHbOHO1kjLnnIt9mtzx_x_jLy0kl7W--7HVWw4Pot4-6C_8L57emDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219301056</pqid></control><display><type>article</type><title>Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo</title><source>MEDLINE</source><source>Oxford Journals - Connect here FIRST to enable access</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Alekseyev, Yuriy O. ; Hamm, Michelle L. ; Essigmann, John M.</creator><creatorcontrib>Alekseyev, Yuriy O. ; Hamm, Michelle L. ; Essigmann, John M.</creatorcontrib><description>Aflatoxin B1 (AFB1), the most potent member of the aflatoxin family of hepatocarcinogens, upon metabolic activation reacts with DNA and forms a population of covalent adducts. The most prevalent adduct, 8,9-dihydro-8-(N7-guanyl-)-9-hydroxyaflatoxin (AFB1-N7-dG), as well as the AFB1 formamidopyrimidine adduct (AFB1-FAPY), resulting from imidazole ring opening of the major adduct, are thought to be responsible for mutations caused by AFB1. The AFB1-N7-dG lesions are rapidly removed in Escherichia coli and mammals, whereas the AFB1-FAPY lesions persist in mammalian cells, which along with the higher stability of this lesion suggests that AFB1-FAPY might significantly contribute to the observed toxicity and carcinogenicity of AFB1 in higher organisms. Other workers have shown in vitro evidence that AFB1-FAPY lesions are substrates for both nucleotide excision repair (NER) and base excision repair (BER). The present study, done in vivo, utilized a modified host cell reactivation assay and showed that AFB1-FAPY lesions are preferentially repaired in E.coli by NER. Comparisons of repair in wild-type, NER-deficient (uvrA), BER-deficient (mutM) and NER/BER double mutant E.coli strains transformed with plasmids enriched for AFB1-N7-dG or AFB1-FAPY lesions indicate that both lesions are efficiently repaired by NER-proficient cells (both wild-type and BER-deficient strains). We have found that the level of activity of the reporter gene is significantly affected by the presence of either lesion in NER-deficient strains due to the lack of repair. This effect is similar in NER-deficient and NER/BER-deficient strains indicating that BER (specifically in the strains we investigated) does not contribute significantly to the repair of these lesions in vivo. Consistent with this finding, in vitro analysis of AFB1-FAPY adduct excision by purified MutM and its functional analog human 8-oxoguanine DNA glycosylase using site-specifically modified oligonucleotides indicates that this lesion is a poor substrate for both proteins compared with canonical substrates for these enzymes, such as 7,8-dihydro-8-oxoguanine and methylformamidopyrimidine.</description><identifier>ISSN: 0143-3334</identifier><identifier>ISSN: 1460-2180</identifier><identifier>EISSN: 1460-2180</identifier><identifier>DOI: 10.1093/carcin/bgh098</identifier><identifier>PMID: 14742311</identifier><identifier>CODEN: CRNGDP</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>2′-deoxyguanine ; 4-dihydropyrimid-5-yl-formamido)-9-hydroxyaflatoxin B1 ; 6-diamino-4-oxo-3 ; 6-diamino-4-oxo-5-(N-methyl)-formamidopyrimidine ; 8-dihydro-8-oxoguanine ; 8-oxoG ; 9-dihydro-8 ; 9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 ; AFB1 ; AFB1-FAPY ; AFB1-N7-dG ; aflatoxin B1 ; Aflatoxin B1 - chemistry ; Aflatoxin B1 - toxicity ; base excision repair ; Base Sequence ; BER ; Biological and medical sciences ; Carcinogenesis, carcinogens and anticarcinogens ; DNA Repair ; FAPY ; formamidopyrimidine ; formamidopyrimidine DNA glycosylase ; Fpg ; HCR ; high pressure liquid chromatography ; hOGG1 ; host cell reactivation ; HPLC ; human 8-oxoguanine DNA glycosylase ; Me-FAPY ; Medical sciences ; NER ; NMR ; nuclear magnetic resonance ; nucleotide excision repair ; Oligonucleotides ; PAGE ; polyacrylamide gel electrophoresis ; Pyrimidines - chemistry ; TEAAC ; tetraethyl ammonium acetate ; Tumors</subject><ispartof>Carcinogenesis (New York), 2004-06, Vol.25 (6), p.1045-1051</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Jun 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3388-745a8dad3b60a7d192efbab0197c61d0551d70d0a662f363588dfc80cd7fbb483</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15877983$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14742311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alekseyev, Yuriy O.</creatorcontrib><creatorcontrib>Hamm, Michelle L.</creatorcontrib><creatorcontrib>Essigmann, John M.</creatorcontrib><title>Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo</title><title>Carcinogenesis (New York)</title><addtitle>Carcinogenesis</addtitle><description>Aflatoxin B1 (AFB1), the most potent member of the aflatoxin family of hepatocarcinogens, upon metabolic activation reacts with DNA and forms a population of covalent adducts. The most prevalent adduct, 8,9-dihydro-8-(N7-guanyl-)-9-hydroxyaflatoxin (AFB1-N7-dG), as well as the AFB1 formamidopyrimidine adduct (AFB1-FAPY), resulting from imidazole ring opening of the major adduct, are thought to be responsible for mutations caused by AFB1. The AFB1-N7-dG lesions are rapidly removed in Escherichia coli and mammals, whereas the AFB1-FAPY lesions persist in mammalian cells, which along with the higher stability of this lesion suggests that AFB1-FAPY might significantly contribute to the observed toxicity and carcinogenicity of AFB1 in higher organisms. Other workers have shown in vitro evidence that AFB1-FAPY lesions are substrates for both nucleotide excision repair (NER) and base excision repair (BER). The present study, done in vivo, utilized a modified host cell reactivation assay and showed that AFB1-FAPY lesions are preferentially repaired in E.coli by NER. Comparisons of repair in wild-type, NER-deficient (uvrA), BER-deficient (mutM) and NER/BER double mutant E.coli strains transformed with plasmids enriched for AFB1-N7-dG or AFB1-FAPY lesions indicate that both lesions are efficiently repaired by NER-proficient cells (both wild-type and BER-deficient strains). We have found that the level of activity of the reporter gene is significantly affected by the presence of either lesion in NER-deficient strains due to the lack of repair. This effect is similar in NER-deficient and NER/BER-deficient strains indicating that BER (specifically in the strains we investigated) does not contribute significantly to the repair of these lesions in vivo. Consistent with this finding, in vitro analysis of AFB1-FAPY adduct excision by purified MutM and its functional analog human 8-oxoguanine DNA glycosylase using site-specifically modified oligonucleotides indicates that this lesion is a poor substrate for both proteins compared with canonical substrates for these enzymes, such as 7,8-dihydro-8-oxoguanine and methylformamidopyrimidine.</description><subject>2′-deoxyguanine</subject><subject>4-dihydropyrimid-5-yl-formamido)-9-hydroxyaflatoxin B1</subject><subject>6-diamino-4-oxo-3</subject><subject>6-diamino-4-oxo-5-(N-methyl)-formamidopyrimidine</subject><subject>8-dihydro-8-oxoguanine</subject><subject>8-oxoG</subject><subject>9-dihydro-8</subject><subject>9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1</subject><subject>AFB1</subject><subject>AFB1-FAPY</subject><subject>AFB1-N7-dG</subject><subject>aflatoxin B1</subject><subject>Aflatoxin B1 - chemistry</subject><subject>Aflatoxin B1 - toxicity</subject><subject>base excision repair</subject><subject>Base Sequence</subject><subject>BER</subject><subject>Biological and medical sciences</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>DNA Repair</subject><subject>FAPY</subject><subject>formamidopyrimidine</subject><subject>formamidopyrimidine DNA glycosylase</subject><subject>Fpg</subject><subject>HCR</subject><subject>high pressure liquid chromatography</subject><subject>hOGG1</subject><subject>host cell reactivation</subject><subject>HPLC</subject><subject>human 8-oxoguanine DNA glycosylase</subject><subject>Me-FAPY</subject><subject>Medical sciences</subject><subject>NER</subject><subject>NMR</subject><subject>nuclear magnetic resonance</subject><subject>nucleotide excision repair</subject><subject>Oligonucleotides</subject><subject>PAGE</subject><subject>polyacrylamide gel electrophoresis</subject><subject>Pyrimidines - chemistry</subject><subject>TEAAC</subject><subject>tetraethyl ammonium acetate</subject><subject>Tumors</subject><issn>0143-3334</issn><issn>1460-2180</issn><issn>1460-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEFv1DAQhS0EokvhyBVZSBxDx3FiO8dSFQqqxKEgob1YE9thXbJxsJNl8-8x2og9zWE-vaf3EfKawXsGDb8yGI0frtqfO2jUE7JhlYCiZAqekg2wihec8-qCvEjpEYAJXjfPyQWrZFVyxjbkcN31OIWjH-gHRrsQ97j3NoxL9Pn6wVG0djZTohgdHaPrXHTD5LHvFxrdiD46S9uFTjtHh9n0LkzeOuqOxicfhpWhI067P7jQ3HPwh_CSPOuwT-7Vei_J94-3327uivuvnz7fXN8XhnOlClnVqCxa3gpAaVlTuq7FFlgjjWAW6ppZCRZQiLLjeZxStjMKjJVd21aKX5K3p9wxht-zS5N-DHMccqUuWcOBQS0yVJwgE0NKeaIe83qMi2ag_0nWJ8n6JDnzb9bQud07e6ZXqxl4twKYDPZdxCHbOHO1kjLnnIt9mtzx_x_jLy0kl7W--7HVWw4Pot4-6C_8L57emDA</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>Alekseyev, Yuriy O.</creator><creator>Hamm, Michelle L.</creator><creator>Essigmann, John M.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>200406</creationdate><title>Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo</title><author>Alekseyev, Yuriy O. ; Hamm, Michelle L. ; Essigmann, John M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3388-745a8dad3b60a7d192efbab0197c61d0551d70d0a662f363588dfc80cd7fbb483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>2′-deoxyguanine</topic><topic>4-dihydropyrimid-5-yl-formamido)-9-hydroxyaflatoxin B1</topic><topic>6-diamino-4-oxo-3</topic><topic>6-diamino-4-oxo-5-(N-methyl)-formamidopyrimidine</topic><topic>8-dihydro-8-oxoguanine</topic><topic>8-oxoG</topic><topic>9-dihydro-8</topic><topic>9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1</topic><topic>AFB1</topic><topic>AFB1-FAPY</topic><topic>AFB1-N7-dG</topic><topic>aflatoxin B1</topic><topic>Aflatoxin B1 - chemistry</topic><topic>Aflatoxin B1 - toxicity</topic><topic>base excision repair</topic><topic>Base Sequence</topic><topic>BER</topic><topic>Biological and medical sciences</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>DNA Repair</topic><topic>FAPY</topic><topic>formamidopyrimidine</topic><topic>formamidopyrimidine DNA glycosylase</topic><topic>Fpg</topic><topic>HCR</topic><topic>high pressure liquid chromatography</topic><topic>hOGG1</topic><topic>host cell reactivation</topic><topic>HPLC</topic><topic>human 8-oxoguanine DNA glycosylase</topic><topic>Me-FAPY</topic><topic>Medical sciences</topic><topic>NER</topic><topic>NMR</topic><topic>nuclear magnetic resonance</topic><topic>nucleotide excision repair</topic><topic>Oligonucleotides</topic><topic>PAGE</topic><topic>polyacrylamide gel electrophoresis</topic><topic>Pyrimidines - chemistry</topic><topic>TEAAC</topic><topic>tetraethyl ammonium acetate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alekseyev, Yuriy O.</creatorcontrib><creatorcontrib>Hamm, Michelle L.</creatorcontrib><creatorcontrib>Essigmann, John M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Carcinogenesis (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alekseyev, Yuriy O.</au><au>Hamm, Michelle L.</au><au>Essigmann, John M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo</atitle><jtitle>Carcinogenesis (New York)</jtitle><addtitle>Carcinogenesis</addtitle><date>2004-06</date><risdate>2004</risdate><volume>25</volume><issue>6</issue><spage>1045</spage><epage>1051</epage><pages>1045-1051</pages><issn>0143-3334</issn><issn>1460-2180</issn><eissn>1460-2180</eissn><coden>CRNGDP</coden><abstract>Aflatoxin B1 (AFB1), the most potent member of the aflatoxin family of hepatocarcinogens, upon metabolic activation reacts with DNA and forms a population of covalent adducts. The most prevalent adduct, 8,9-dihydro-8-(N7-guanyl-)-9-hydroxyaflatoxin (AFB1-N7-dG), as well as the AFB1 formamidopyrimidine adduct (AFB1-FAPY), resulting from imidazole ring opening of the major adduct, are thought to be responsible for mutations caused by AFB1. The AFB1-N7-dG lesions are rapidly removed in Escherichia coli and mammals, whereas the AFB1-FAPY lesions persist in mammalian cells, which along with the higher stability of this lesion suggests that AFB1-FAPY might significantly contribute to the observed toxicity and carcinogenicity of AFB1 in higher organisms. Other workers have shown in vitro evidence that AFB1-FAPY lesions are substrates for both nucleotide excision repair (NER) and base excision repair (BER). The present study, done in vivo, utilized a modified host cell reactivation assay and showed that AFB1-FAPY lesions are preferentially repaired in E.coli by NER. Comparisons of repair in wild-type, NER-deficient (uvrA), BER-deficient (mutM) and NER/BER double mutant E.coli strains transformed with plasmids enriched for AFB1-N7-dG or AFB1-FAPY lesions indicate that both lesions are efficiently repaired by NER-proficient cells (both wild-type and BER-deficient strains). We have found that the level of activity of the reporter gene is significantly affected by the presence of either lesion in NER-deficient strains due to the lack of repair. This effect is similar in NER-deficient and NER/BER-deficient strains indicating that BER (specifically in the strains we investigated) does not contribute significantly to the repair of these lesions in vivo. Consistent with this finding, in vitro analysis of AFB1-FAPY adduct excision by purified MutM and its functional analog human 8-oxoguanine DNA glycosylase using site-specifically modified oligonucleotides indicates that this lesion is a poor substrate for both proteins compared with canonical substrates for these enzymes, such as 7,8-dihydro-8-oxoguanine and methylformamidopyrimidine.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>14742311</pmid><doi>10.1093/carcin/bgh098</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0143-3334
ispartof Carcinogenesis (New York), 2004-06, Vol.25 (6), p.1045-1051
issn 0143-3334
1460-2180
1460-2180
language eng
recordid cdi_proquest_journals_219301056
source MEDLINE; Oxford Journals - Connect here FIRST to enable access; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects 2′-deoxyguanine
4-dihydropyrimid-5-yl-formamido)-9-hydroxyaflatoxin B1
6-diamino-4-oxo-3
6-diamino-4-oxo-5-(N-methyl)-formamidopyrimidine
8-dihydro-8-oxoguanine
8-oxoG
9-dihydro-8
9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1
AFB1
AFB1-FAPY
AFB1-N7-dG
aflatoxin B1
Aflatoxin B1 - chemistry
Aflatoxin B1 - toxicity
base excision repair
Base Sequence
BER
Biological and medical sciences
Carcinogenesis, carcinogens and anticarcinogens
DNA Repair
FAPY
formamidopyrimidine
formamidopyrimidine DNA glycosylase
Fpg
HCR
high pressure liquid chromatography
hOGG1
host cell reactivation
HPLC
human 8-oxoguanine DNA glycosylase
Me-FAPY
Medical sciences
NER
NMR
nuclear magnetic resonance
nucleotide excision repair
Oligonucleotides
PAGE
polyacrylamide gel electrophoresis
Pyrimidines - chemistry
TEAAC
tetraethyl ammonium acetate
Tumors
title Aflatoxin B1 formamidopyrimidine adducts are preferentially repaired by the nucleotide excision repair pathway in vivo
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aflatoxin%20B1%20formamidopyrimidine%20adducts%20are%20preferentially%20repaired%20by%20the%20nucleotide%20excision%20repair%20pathway%20in%20vivo&rft.jtitle=Carcinogenesis%20(New%20York)&rft.au=Alekseyev,%20Yuriy%20O.&rft.date=2004-06&rft.volume=25&rft.issue=6&rft.spage=1045&rft.epage=1051&rft.pages=1045-1051&rft.issn=0143-3334&rft.eissn=1460-2180&rft.coden=CRNGDP&rft_id=info:doi/10.1093/carcin/bgh098&rft_dat=%3Cproquest_cross%3E729198081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219301056&rft_id=info:pmid/14742311&rfr_iscdi=true